RxDoctor Payments Data

Leandra Ogas

Family · Las Cruces, NMNPI 1043766249

Payments from drug & device makers

$1,778in general payments, 2019–2025

Across 73 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$629
  • Lilly USA, LLC$265
  • Novo Nordisk$152
  • Globus Medical$146
  • GSK$138
  • Amgen$83
  • plus $365 from 9 others

What the payments were for

  • Food & beverage$1,778100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,778 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$37,138
Medicare patients
127
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$41,285
JardianceEmpagliflozin28$29,871
EliquisApixaban18$22,376
FarxigaDapagliflozin Propanediol20$19,980
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,809
Quetiapine Fumarate11$1,192
Levothyroxine Sodium95$968
Atorvastatin Calcium67$894
Albuterol Sulfate HfaAlbuterol Sulfate48$886
Rosuvastatin Calcium49$769
Tamsulosin Hcl32$718
SynthroidLevothyroxine Sodium13$704
Gabapentin46$694
Lisinopril96$623
Omeprazole34$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$41,28534 claims
Boehringer IngelheimJardiance$59$29,87128 claims
PfizerEliquis$82$22,37618 claims
AstraZenecaFarxiga$629$19,98020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →